Drug intelligence / Profile preview

hydrocortisone + polymyxin b sulfate + bacitracin zinc + neomycin

Development stage
Approved
Lead developer
Pfizer
Modality
Small Molecules
Administration
Ophthalmic, Topical
01

Overview

Hydrocortisone + polymyxin b sulfate + bacitracin zinc + neomycin is a marketed fixed-dose ophthalmic anti-infective and corticosteroid combination, historically sold under the brand name Cortisporin. It combines **hydrocortisone**, a glucocorticoid receptor agonist that suppresses ocular inflammation, with **neomycin**, **polymyxin B**, and **bacitracin**, antibacterial agents that broaden topical coverage against susceptible bacterial eye pathogens by inhibiting ribosomal protein synthesis, disrupting the bacterial outer membrane, and inhibiting bacterial cell wall synthesis, respectively. The ointment has been used for steroid-responsive inflammatory ocular conditions where bacterial infection is present or there is risk of infection, including inflammatory conditions of the conjunctiva, cornea, and anterior segment of the globe, chronic anterior uveitis, and corneal injury from chemical, radiation, or thermal burns or foreign body penetration. The ophthalmic ointment formulation described in labeling contains hydrocortisone 1% with neomycin sulfate, polymyxin B sulfate, and bacitracin zinc in a petrolatum and mineral oil base.

Brand names
Cortisporin
Other names
neomycin + polymyxin b sulfate + bacitracin zinc + hydrocortisoneneomycin and polymyxin b sulfates + bacitracin zinc + hydrocortisone ophthalmic ointmenthydrocortisone + polymyxin b sulfate + bacitracin zinc + neomycin ophthalmic ointment
02

Targets

Bacterial RibosomeLipid AGR (Glucocorticoid receptor)C55-PP (Undecaprenyl pyrophosphate)

Beyond the preview

Go deeper on hydrocortisone + polymyxin b sulfate + bacitracin zinc + neomycin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on hydrocortisone + polymyxin b sulfate + bacitracin zinc + neomycin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call